-DOCSTART- -X- O
Artificial -X- _ B-Intervention
blood -X- _ I-Intervention
is -X- _ O
an -X- _ O
innovative -X- _ O
concept -X- _ O
of -X- _ O
transfusion -X- _ O
medicine -X- _ O
where -X- _ O
specifically -X- _ O
designed -X- _ O
compounds -X- _ O
perform -X- _ O
the -X- _ O
task -X- _ O
of -X- _ O
transport -X- _ O
and -X- _ O
delivery -X- _ O
of -X- _ O
oxygen -X- _ O
in -X- _ O
the -X- _ O
body -X- _ O
to -X- _ O
replace -X- _ O
this -X- _ O
function -X- _ O
of -X- _ O
allogenic -X- _ O
human -X- _ O
blood -X- _ O
transfusion. -X- _ O
Several -X- _ O
molecules -X- _ O
have -X- _ O
been -X- _ O
developed -X- _ O
in -X- _ O
the -X- _ O
past -X- _ O
few -X- _ O
decades -X- _ O
to -X- _ O
achieve -X- _ O
this -X- _ O
objective -X- _ O
and -X- _ O
continous -X- _ O
refinements -X- _ O
are -X- _ O
being -X- _ O
continuously -X- _ O
made -X- _ O
in -X- _ O
the -X- _ O
quest -X- _ O
of -X- _ O
the -X- _ O
ideal -X- _ O
blood -X- _ O
substitute. -X- _ O
Currently -X- _ O
, -X- _ O
available -X- _ O
technology -X- _ B-Intervention
manufactures -X- _ I-Intervention
artificial -X- _ I-Intervention
blood -X- _ I-Intervention
from -X- _ I-Intervention
haemoglobin -X- _ I-Intervention
obtained -X- _ I-Intervention
from -X- _ I-Intervention
outdated -X- _ I-Intervention
human -X- _ I-Intervention
/ -X- _ I-Intervention
bovine -X- _ I-Intervention
blood -X- _ I-Intervention
( -X- _ I-Intervention
Haemoglobin -X- _ I-Intervention
Based -X- _ I-Intervention
Oxygen -X- _ I-Intervention
Carriers -X- _ I-Intervention
) -X- _ I-Intervention
or -X- _ I-Intervention
utilizing -X- _ I-Intervention
Perfluorocarbons. -X- _ I-Intervention
These -X- _ O
synthetic -X- _ O
blood -X- _ O
substitutes -X- _ O
are -X- _ O
advantageous -X- _ O
in -X- _ O
that -X- _ O
they -X- _ O
do -X- _ B-Outcome
not -X- _ I-Outcome
require -X- _ I-Outcome
compatibility -X- _ I-Outcome
testing -X- _ I-Outcome
, -X- _ I-Outcome
are -X- _ I-Outcome
free -X- _ I-Outcome
from -X- _ I-Outcome
blood -X- _ I-Outcome
borne -X- _ I-Outcome
infections -X- _ I-Outcome
, -X- _ I-Outcome
have -X- _ I-Outcome
prolonged -X- _ I-Outcome
shelf -X- _ I-Outcome
life -X- _ I-Outcome
and -X- _ I-Outcome
do -X- _ I-Outcome
not -X- _ I-Outcome
require -X- _ I-Outcome
refrigeration. -X- _ I-Outcome
Artificial -X- _ B-Intervention
blood -X- _ I-Intervention
is -X- _ O
projected -X- _ O
to -X- _ O
have -X- _ O
a -X- _ O
significant -X- _ O
impact -X- _ O
on -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
medical -X- _ O
care -X- _ O
in -X- _ O
the -X- _ O
future. -X- _ O
It -X- _ O
can -X- _ O
complement -X- _ O
the -X- _ O
current -X- _ O
blood -X- _ O
products -X- _ O
for -X- _ O
transfusion -X- _ O
and -X- _ O
create -X- _ O
a -X- _ O
stable -X- _ O
supply -X- _ O
of -X- _ O
safe -X- _ O
and -X- _ O
effective -X- _ O
products. -X- _ O
It -X- _ O
is -X- _ O
likely -X- _ O
to -X- _ O
reduce -X- _ B-Outcome
the -X- _ I-Outcome
requirements -X- _ I-Outcome
of -X- _ I-Outcome
blood -X- _ I-Outcome
transfusions -X- _ I-Outcome
drastically -X- _ I-Outcome
especially -X- _ I-Outcome
in -X- _ I-Outcome
settings -X- _ I-Outcome
of -X- _ I-Outcome
trauma -X- _ I-Outcome
and -X- _ I-Outcome
surgery -X- _ I-Outcome
thereby -X- _ I-Outcome
reducing -X- _ I-Outcome
the -X- _ I-Outcome
reliance -X- _ I-Outcome
on -X- _ I-Outcome
banked -X- _ I-Outcome
donated -X- _ I-Outcome
blood -X- _ I-Outcome
. -X- _ O

